Funds Holding Novell Inc

 
News Articles for Novell Inc top ^
2014/12/2
FARMINGDALE, N.Y. , Dec.
Sign-up for Novel BoneScalpel Technique Published in Operative Neurosurgery investment picks
2014/12/2
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today the completion of enrollment in the Company’s 400-patient Phase 3 registration trial (“Rocket 1”) of Rhopressa TM , a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Sign-up for Aerie Pharmaceuticals Completes Enrollment in Phase 3 Registration Trial (“Rocket 1”) of Rhopressa™, Novel Triple-Action Product to Lower Intraocular Pressure in Patients with Glaucoma investment picks
2014/12/2
--Candidate Will Target Two Undisclosed Immune Checkpoints --Anti-TIM-3 Antibody Data to be Presented Today at the AACR Conference in Orlando WALTHAM, Mass.
Sign-up for TESARO and AnaptysBio Expand Immuno-Oncology Collaboration to Include Novel Bispecific Antibody Candidate investment picks
2014/12/10
SOUTH SAN FRANCISCO, Calif., Dec.
Sign-up for Calithera Presents Novel Pharmacodynamic Assay Data Confirming Glutaminase Inhibition in Tumor Biopsy Samples From Patients Treated With CB-839 investment picks
2014/12/9
GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that data from research related to the company’s E-Selectin antagonist (GMI-1271), focusing on its potential in treating blood cancers and coagulation disorders, were highlighted this week through four oral presentations and one poster session at the 2014 American Society of Hematology Annual Meeting in San Francisco.
Sign-up for GlycoMimetics Highlights Potential Therapeutic Benefits of Its Novel E-Selectin Antagonist at 56th ASH Annual Meeting investment picks
2014/12/9
Presentations at SABCS and SUO Reveal Company's Ability to Detect Breast and Bladder Cancers in Blood and Urine, Respectively SAN ANTONIO , Dec.
Sign-up for Genomic Health Advances Development of Novel Liquid Biopsy-Based Cancer Tests investment picks
2014/12/8
- Clinical safety data for IMO-8400 support dose escalation in ongoing Phase 1/2 trials CAMBRIDGE, Mass., Dec.
Sign-up for Idera Pharmaceuticals Presents Data Supporting IMO-8400 as Novel Therapy for Genetically Defined Forms of B-Cell Lymphoma at Annual ASH Meeting investment picks
2015/1/7
- Company expands Canadian dermatology portfolio – MISSISSAUGA, ON , Jan.
Sign-up for Cipher Pharmaceuticals acquires Canadian commercialization rights to novel antibacterial compound Ozenoxacin investment picks
2015/1/5
Exelis (NYSE: XLS) and TrafficLand, the largest authorized aggregator of live traffic video in the United States, have partnered to apply Helios next-generation image science to America’s largest traffic camera network.
Sign-up for Exelis and TrafficLand® partner to deliver novel weather information via Helios™ digital platform investment picks
2015/1/5
Alliance Combines Amgen's Oncology Targets and Kite's Leading CAR T Cell Therapy Platform to Develop new Therapeutic Candidates Kite to Receive a $60 Million Upfront Payment From Amgen and Eligible for up to $525 Million in Regulatory and Sales Milestone Payments per Amgen Program; Plus, Tiered High Single- to Double-Digit Royalties for Sales and License of Kite's Intellectual Property for CAR T Cell Products Amgen Eligible to Receive up to $525 Million in Milestone Payments per Kite Program; Plus, Tiered Single-Digit Sales Royalties Kite to Host Conference Call Today at 4:00 PM Eastern Time THOUSAND OAKS, Calif.
Sign-up for Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy Collaboration to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies investment picks
2015/1/5
REDWOOD CITY, Calif., Jan.
Sign-up for OncoMed Doses First Patient in Phase 1 Clinical Trial of Novel Anti-DLL4/VEGF Bispecific Antibody investment picks
2014/12/29
Fluidigm Corporation (NASDAQ:FLDM) today announced a new single-cell application for its C1 TM system that improves whole genome sequencing of individual cells.
Sign-up for New Single-Cell Whole Genome Sequencing Workflow Allows Discovery of Novel Cellular Heterogeneity investment picks
2014/12/23
BioLineRx Ltd.
Sign-up for BioLineRx Out-Licenses Novel Skin Lesion Treatment to Omega Pharma investment picks
2014/12/18
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that it has acquired, through a subsidiary, OncoEthix, a Swiss-based privately held biotechnology company specializing in oncology drug development.
Sign-up for Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers investment picks
2015/1/9
Incyte Corporation (Nasdaq:INCY) and Agenus Inc. (Nasdaq:AGEN) today announced a global license, development and commercialization agreement focused on novel immuno-therapeutics using Agenus’ proprietary Retrocyte Display™ antibody discovery platform.
Sign-up for Incyte and Agenus Announce Global Alliance to Develop Novel Immuno-Oncology Antibodies investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Funds Holding Novell Inc
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Funds Holding Novartis AG Adr  |  Next: Funds Holding Novo Nordisk A/S